Merck: A return to health?
Despite industry pressure, the drugmaker is focused on boosting its future pipeline.
By Ben Shepherd, Investing Daily
Merck (MRK) has failed to excite the market about its prospects as sales and earnings have fallen largely in line with Wall Street estimates over the past several quarters, with few surprises to the upside.
Merck has faced pressure from the looming patent expiration of its blockbuster allergy drug Singulair, which goes off patent in August. With annual sales of about $5.2 billion, Singulair has contributed about 11.1% toward Merck's annual revenue over the past two years, so it's easy to understand why investors might be nervous.
But Merck still boasts a robust development pipeline, and it plans to file approval applications with the FDA for three new drugs this year, five next year and seven in 2014.
In fact, the company will submit more FDA approval applications over the next few years than any of the other major pharmaceutical outfit.
While the odds of all 15 applications being approved are slim, data from ongoing clinical trials for most of Merck's drug candidates appear promising.
In an effort to bolster its development pipeline, Merck acquired Schering-Plough in 2009 and absorbed that company's deep bench of attractive drug candidates at various stages of trials.
Now, some of the best of that former company's slate of drug candidates, such as suvorexant for the treatment of insomnia, are in late-stage trials and will be submitted for FDA approval over the next couple of years.
Meanwhile, the company is financially strong, with attractive free cash flow and relatively low debt. Additionally, Merck's shares offer an enticing 4.5% dividend yield with a 77% payout ratio, so there's room for future dividend growth and research investment.
With manageable patent expirations and a solid dividend, Merck is an excellent play on a return to health for the American pharmaceutical industry.
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The US isn't strong enough not to care about them now. But one day it will be.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.